Aurobindo Pharma has received the Establishment Inspection Report (EIR) with Voluntary Action Initiated (VAI) status from the US Food and Drug Administration (USFDA) for its Unit IV, a general injectable formulation manufacturing facility situated at Pashamylaram, Hyderabad. The USFDA had inspected company's Unit IV from November 4, 2019 to November 13, 2019.
Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.
